Table 1.
Characteristics of patients with Graves’ disease with orbitopathy (n=49)
| Variables | Graves’ disease with orbitopathy |
|---|---|
| Age at onset (years) | 33 (26, 40) |
| Female (%) | 28 (57.1%) |
| GD duration (months) | 24 (9.5, 60) |
| Therapy for GD | |
| Anti-thyroid drugs | 45 (91.8%) |
| Radioiodine ablation | 1 (2%) |
| Surgery | 3 (6.1%) |
| No treatment | 1 (2%) |
| Relapse after treatment | 21 (42.9%) |
| Severity of eye disease | |
| Mild | 25 (51.0%) |
| Moderate-severe | 23 (46.9%) |
| Sight-threatening | 1 (2.0%) |
| Clinically active disease | 10 (20.4%) |
| TRAb titer (IU/l) | 20.4 (4, 58) |
| TRAb positivity (>1.5 IU/l) | 44 (90.7%) |
| TPOAb titers (IU/ml) | 283 (81, 1000) |
| TPOAb positivity (>35 IU/ml) | 39 (78.6%) |
Median (inter-quartile range), n (%), GD: Graves’ disease, GO: Graves’ orbitopathy, TRAb: thyrotropin receptor antibody, TPOAb: Thyroid peroxidase antibody